​

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARQT Stock Forecast

Arcutis Biotherapeutics (ARQT) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $19.00, with a high of $19.00 and a low of $19.00. This represents a 38.48% increase from the last price of $13.72.

- $4 $8 $12 $16 $20 High: $19 Avg: $19 Low: $19 Last Closed Price: $13.72

ARQT Stock Rating

Arcutis Biotherapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 0 Hold (0.00%), 1 Sell (20.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 0 4 Strong Sell Sell Hold Buy Strong Buy

ARQT Forecast vs Benchmarks

TypeNameUpside
StockArcutis Biotherapeutics38.48%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$19.00$18.33
Last Closing Price$13.72$13.72$13.72
Upside/Downside-38.48%33.60%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25341--8
Dec, 24341--8
Nov, 24241--7
Oct, 24241--7
Sep, 24242--8
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 30, 2024Douglas TsaoH.C. Wainwright$19.00$14.2033.80%38.48%
May 15, 2024Serge BelangerNeedham$18.00$8.13121.40%31.20%
May 15, 2024Uy EarMizuho Securities$18.00$8.13121.40%31.20%
Jan 02, 2024Mizuho Securities$8.00$3.43133.24%-41.69%
Dec 13, 2022Morgan Stanley$51.00$16.58207.60%271.72%
Apr 27, 2022Eric ChaGoldman Sachs$37.00$19.6288.58%169.68%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 28, 2024NeedhamBuyBuyhold
Aug 28, 2024JefferiesBuyinitialise
Aug 15, 2024Cowen & Co.BuyBuyhold
Jul 10, 2024NeedhamBuyBuyhold
May 15, 2024NeedhamBuyBuyhold
Apr 12, 2024NeedhamBuyBuyhold
Dec 13, 2022Morgan StanleyOverweightOverweighthold
Apr 26, 2022Zacks Investment ResearchSelldowngrade

Financial Forecast

EPS Forecast

$-7 $-5 $-3 $-1 $1 $3 $4 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.84$-3.78-----
Avg Forecast$-5.93$-3.92$-1.32$-0.83$0.05$1.51$2.44
High Forecast$-6.73$-4.02$-1.38$-0.96$-0.11$0.14$2.15
Low Forecast$-4.99$-3.81$-1.18$-0.56$0.20$3.23$2.82
Surprise %-1.52%-3.57%-----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.69M$59.61M-----
Avg Forecast$2.97M$57.58M$185.46M$288.65M$423.15M$635.90M$788.81M
High Forecast$2.61M$52.28M$181.24M$267.54M$419.09M$577.34M$716.17M
Low Forecast$3.28M$64.49M$190.80M$311.07M$427.21M$712.20M$883.44M
Surprise %23.99%3.52%-----

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-321.29M$-262.14M-----
Avg Forecast$-411.14M$-271.19M$-88.60M$-52.46M$3.08M$157.37M$168.97M
High Forecast$-466.18M$-278.68M$-95.73M$-66.23M$-7.84M$9.65M$148.74M
Low Forecast$-345.49M$-263.71M$-81.47M$-38.68M$13.99M$223.66M$195.32M
Surprise %-21.85%-3.34%-----

ARQT Forecast FAQ

Is Arcutis Biotherapeutics stock a buy?

Arcutis Biotherapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Arcutis Biotherapeutics is a favorable investment for most analysts.

What is Arcutis Biotherapeutics's price target?

Arcutis Biotherapeutics's price target, set by 5 Wall Street analysts, averages $19 over the next 12 months. The price target range spans from $19 at the low end to $19 at the high end, suggesting a potential 38.48% change from the previous close price of $13.72.

How does Arcutis Biotherapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Arcutis Biotherapeutics stock forecast shows a 38.48% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Arcutis Biotherapeutics over the past three months?

  • January 2025: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Arcutis Biotherapeutics’s EPS forecast?

Arcutis Biotherapeutics's average annual EPS forecast for its fiscal year ending in December is -1.32 for 2024, a -65.08% decrease from the reported $-3.78 in 2023. The prediction for 2025 is $-0.83, $0.05 for 2026, $1.51 for 2027, and $2.44 for 2028.

What is Arcutis Biotherapeutics’s revenue forecast?

Arcutis Biotherapeutics's average annual revenue forecast for its fiscal year ending in December is $185.46M for 2024, a 211.15% increase from the reported $59.61M in 2023. The forecast for 2025 is $288.65M, $423.15M for 2026, $635.9M for 2027, and $788.81M for 2028.

What is Arcutis Biotherapeutics’s net income forecast?

For its fiscal year ending in December, Arcutis Biotherapeutics's average annual net income forecast is $-88.602M for 2024, reflecting a -66.20% decrease from the reported $-262M in 2023. The projection for 2025 is $-52.455M, $3.08M for 2026, $157.37M for 2027, and $168.97M for 2028.